Danaher

Siemens Healthineers received clearance for its Dimension Exl High-Sensitivity Troponin I Assay used to diagnose acute myocardial infarction.

The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.

The digital pathology system can be used for primary diagnosis as a result of the 510(k) clearance, which followed a multicenter study conducted at five clinical sites.

The company said that the DxA 5000 reduces the number of required manual steps and can shorten the preanalytical processing time by up to 73 percent.

The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.

A brief recap of Diagnostics news the week of Mar 8, 2019: Danaher, Labcorp, Quest, and More

Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.